Vanguard Capital Management’s Definium Therapeutics DFTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$61.6M Buy
1,618,507
+132,053
+9% +$5.56M ﹤0.01% 1786
2026
Q2
$69.9M Buy
1,486,454
+389,476
+36% +$9.6M ﹤0.01% 1755
2026
Q1
$20.7M Buy
+1,096,978
New +$18.6M ﹤0.01% 2324

Other funds holding DFTX

Vanguard Capital Management's DFTX Position: Q3 2026 in Review

Vanguard Capital Management increased its Definium Therapeutics (DFTX) stake by 8.9% in Q3 2026, buying an estimated $5.56M and bringing the position to 1,618,507 shares worth $61.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1786.

Vanguard Capital Management first reported a position in DFTX in Q1 2026 and has held it in 3 quarters since. The position peaked at $69.9M in Q2 2026. 354 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.

  • Vanguard Capital Management held 1,618,507 shares of Definium Therapeutics worth $61.6M as of Q3 2026.
  • Vanguard Capital Management bought 132,053 Definium Therapeutics shares in Q3 2026, an estimated $5.56M.
  • Definium Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #1786 holding.
  • Vanguard Capital Management first reported a position in Definium Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Definium Therapeutics position peaked at $69.9M in Q2 2026.
  • 354 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.